ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0924

Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid

Aakash V Patel1, Sarah L Morgan1, Ralph Green2, Maria Danila1, Tony R Merriman1, Keith Wanzeck1, Hamdy Ahmed3 and Angelo Gaffo1, 1University of Alabama at Birmingham, Birmingham, AL, 2Departments of Pathology and Medicine, University of California Davis at Sacramento, Sacramento, CA, 3University of South Alabama, Mobile, AL

Meeting: ACR Convergence 2022

Keywords: Disease-Modifying Antirheumatic Drugs (Dmards), nutrition, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory arthritis in which the immune system targets synovial joints. Methotrexate, a dihydrofolate reductase and aminoimidazole-4-carboxamide ribonucleotide transformylase inhibitor, serves as the first-line treatment for RA due to its efficacy and accessibility. However, the antifolate properties of methotrexate, which can lead to side effects such as cytopenias and gastrointestinal symptoms, limit its usefulness in some patients with RA. Furthermore, patients treated with methotrexate require concurrent folic acid supplementation and are uniquely at risk for vitamin B12 deficiency and hyperhomocysteinemia due to biochemical processes involving folate, methotrexate, and vitamin B12.

Methods: In this cross-sectional study we compared plasma vitamin B12, methylmalonic acid, and homocysteine levels between 50 RA patients treated with methotrexate and folic acid and 49 RA patients using other DMARDs. All patients met the 2010 American College of Rheumatology RA classification criteria and were participants of an established RA inception cohort. The patients selected for this study were matched by age, sex, and ethnicity. A Chi-square goodness of fit test was utilized to compare the proportion of patients in both groups with low, normal, and/or high plasma vitamin B12, methylmalonic acid, and homocysteine levels per the laboratory’s specification of the normal range for these measurements.

Results: There were 10 men and 42 White individuals in each group. Those in the methotrexate and folic acid group had received a mean (SD) cumulative methotrexate dose of 184 (72) decigrams over 11 (4) years and had a mean (SD) age of 63 (11) years compared to 59 (11) years for patients on other therapies (Table 1). Our findings revealed elevated plasma homocysteine levels in 37 (74%) RA patients on methotrexate and folic acid compared to only 27 (55%) patients on other therapies (Chi-square p-value 0.049) (Table 2). We did not find differences in the proportion of patients with low, normal, or high plasma vitamin B12 and methylmalonic acid levels between the two groups.

Conclusion: Our data show high plasma homocysteine levels among RA patients treated with methotrexate and folic acid. While the proportion of patients with low plasma vitamin B12 levels did not significantly differ between the two groups, elevated plasma homocysteine is a more sensitive marker of vitamin B12 deficiency. Additional studies are needed to evaluate for clinical features of vitamin B12 deficiency and hyperhomocysteinemia and determine if monitoring of vitamin B12 status and supplementation are warranted among RA patients treated with methotrexate and folic acid.

Supporting image 1

Table 1: Demographics of RA patients in both study groups and methotrexate usage among RA patients treated with methotrexate and folic acid; MTX+ FA+ = RA patients treated with methotrexate and folic acid; MTX- FA- = RA patients on therapies without methotrexate and folic acid; SD = standard deviation; MTX = methotrexate; FA = folic acid

Supporting image 2

Table 2: Proportion of RA patients on methotrexate and folic acid and those on other therapies with low, normal, or high levels of plasma B12, methylmalonic acid, and homocysteine, as determined by laboratory specifications; MTX+ FA+ = RA patients treated with methotrexate and folic acid; MTX- FA- = RA patients on therapies without methotrexate and folic acid; MTX = methotrexate; FA = folic acid


Disclosures: A. Patel, None; S. Morgan, None; R. Green, None; M. Danila, UCB, Pfizer; T. Merriman, None; K. Wanzeck, None; H. Ahmed, None; A. Gaffo, None.

To cite this abstract in AMA style:

Patel A, Morgan S, Green R, Danila M, Merriman T, Wanzeck K, Ahmed H, Gaffo A. Vitamin B12 Status and Hyperhomocysteinemia in Patients with Rheumatoid Arthritis Treated with Methotrexate and Folic Acid [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/vitamin-b12-status-and-hyperhomocysteinemia-in-patients-with-rheumatoid-arthritis-treated-with-methotrexate-and-folic-acid/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vitamin-b12-status-and-hyperhomocysteinemia-in-patients-with-rheumatoid-arthritis-treated-with-methotrexate-and-folic-acid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology